The FDA has approved Gamida Cell’s omidubicel-onlv, now to be marketed as Omisirge, in patients over 12 years of age with blood cancers, the company announced Monday.
https://www.pharmalive.com/wp-content/uploads/2021/08/Ipsen-Voluntarily-Withdraws-FDA-Submission-for-FOP-Drug-BioSpace-8-13-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-04-18 10:48:042023-04-18 10:48:04Gamida's long regulatory road ends in approval of blood cancer cell therapy
